Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBD for Acute Anticipatory Anxiety in Advanced Breast Cancer
NCT04482244Phase 2Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jan 2022
- Primary completion
- Mar 2023
- Countries
- 1
01
Overview
A Phase 2 trial of cannabidiol in anxiety disorder, sponsored by Dana-Farber Cancer Institute. Started Jan 2022; status: active, not recruiting.
02
Drugs
cannabidiol
03
Conditions
anxiety disorder
Beyond the preview
Go deeper on NCT04482244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04482244.